Saul Genuth

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

Faramarz Ismail‐Beigi, Timothy E. Craven, Mary Ann Banerji et al. · The Lancet · 2010 · 1.4K citations · Full text

Metabolic Syndrome, Diabetes Management, Health Policy +11

Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial—Revisited

John M. Lachin, Saul Genuth, David M. Nathan et al. · Diabetes · 2008 · 543 citations · Full text

Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial

Rodica Pop‐Busui, Gregory W. Evans, Hertzel C. Gerstein et al. · Diabetes Care · 2010 · 526 citations · Full text

Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial.

Vincent M. Monnier, O. Bautista, Danelle Kenny et al. · Diabetes · 1999 · 460 citations

Collagen Products, Metabolic Syndrome, Type 1 +12

Glycation and Carboxymethyllysine Levels in Skin Collagen Predict the Risk of Future 10-Year Progression of Diabetic Retinopathy and Nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications Participants With Type 1 Diabetes

Saul Genuth, Wanjie Sun, Patricia A. Cleary et al. · Diabetes · 2005 · 422 citations · Full text